Commentary|Videos|August 14, 2023

Unpacking Regenerative Medicines and Start-Up Funding with Luis Alvarez

Luis Alvarez, PhD, founder of Theradaptive, candidly discusses how his regenerative therapy start-up evolved and secured start-up funding.

Luis Alvarez, PhD, is the founder of Theradaptive, a biotech start-up focused on regenerative medicines. In this candid discussion with Grant Playter, associate editor, Luis discusses his company’s regenerative bone therapy, how it evolved from his experiences in Iraq, how Theradaptive secured funding in a lukewarm venture capital market, and more.

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

October 13th, 2026

Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC

Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.

October 13th, 2026

Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree

Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.

IoT Internet of Things, Internet network technology, digital software development, big data concept | Image Credit: ©tippapatt -stock.adobe.com

October 13th, 2026

Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0

This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.

October 12th, 2026

PharmTech AI Pulse Check: AI Watermark Vulnerability

PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.

October 9th, 2026

Q&A: Patient-Centric Drug Development Should Start at Product Definition

Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.

FDA approves oral antiviral pritelivir for drug-resistant herpes sores in immunocompromised patients.

October 9th, 2026

Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral

The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.